AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M or other acquired mutations are sensitive to the Aurora B (AURKB) inhibitors barasertib and S49...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Nat Commun
Auteurs principaux: Bertran-Alamillo, Jordi, Cattan, Valérie, Schoumacher, Marie, Codony-Servat, Jordi, Giménez-Capitán, Ana, Cantero, Frédérique, Burbridge, Mike, Rodríguez, Sonia, Teixidó, Cristina, Roman, Ruth, Castellví, Josep, García-Román, Silvia, Codony-Servat, Carles, Viteri, Santiago, Cardona, Andrés-Felipe, Karachaliou, Niki, Rosell, Rafael, Molina-Vila, Miguel-Angel
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6472415/
https://ncbi.nlm.nih.gov/pubmed/31000705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-09734-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires